Study finds testicular cancer rates on the rise among males aged 15-34
SAN DIEGO — Rates of testicular cancer among young men have risen significantly over the last two decades across racial and ethnic groups, according to a new study, and researchers are wondering what accounts for it.
The study, scheduled for presentation Sunday at the 108th annual scientific meeting of the American Urological Association in San Diego, found that testicular cancer – the most common cancer among males between 15 and 34 – still had the highest incidence among Caucasians, but had risen 5.6% among Hispanics between 2002 and 2009, meaning Hispanics had the second highest rates, while African-Americans had the lowest.
Between 1992 and 2009, the rate among Caucasians rose from 7.5-per-100,000 people to 8.6-per-100,000, while the rate among Hispanics rose from 4-per-100,000 to 6.3-per-100,000, and the rate among African-Americans rose from 0.7-per-100,000 to 1.7-per-100,000.
"More research is needed to shed light on why the incidence is up nationwide and if any environmental factors or co-morbidities impact disease formation," University of Kansas Medical Center urology professor and director of urologic oncology Jeff Holzbeierlein said. "These new data confirm Hispanic-Americans should speak with their doctor about risk factors and be even more vigilant with their testicular health."
Prasco to host NCCAA Division I and II baseball World Series
MASON, Ohio — Ohio pharmaceutical company Prasco will host the National Christian College Athletic Association championships here at Prasco Park in May, the company announced today.
College teams from all over the country will descend on Prasco Park to compete in its Division World Series May 8 to 11, and May 15 to 18.
Division II games will begin on May 8, after a service day at Matthew 25 Ministries and banquet on May 7. The Division II opening games will be on May 8 at 1 p.m. at Prasco Park and Legacy Field, adjacent to Prasco Park. The NCCAA championship game will be played May 11 at 2 p.m.
Then on May 15, Division I games will begin after a service day on May 14 at Matthew 25 Ministries and banquet the night before. Division I opening games will start at 10 a.m. on May 15 at Prasco Park and Legacy Field. The Division I championship game will be played on May 18 at 2 p.m. at Prasco Park.
Admission to both baseball championships is free and attendees will have opportunities to participate in activities and contests throughout the tournament. Fan amenities will include complimentary food and drink, speed pitch, wiffle ball, an obstacle course, bungee run, face painting and more.
All community and media members are welcome and encouraged to attend.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.
Actavis sales up 24% in first quarter 2013
PARSIPPANY, N.J. — Actavis’ had $1.9 billion in sales in first quarter 2013, the drug maker said.
The latest figure represented a 24% increase from first quarter 2012’s $1.52 billion. "The new Actavis is off to a strong start in 2013, and as a result, we are increasing our 2013 forecast based on the strong performance and execution against our objectives to date," president and CEO Paul Bisaro said.
The company touted several new products that launched during the quarter, including generic versions of Reckitt Benckiser’s opioid dependence drug Suboxone (buprenorphine) and an authorized generic version of GlaxoSmithKline’s herpes drug Zovirax (aciclovir). Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under a deal between the brand-name drug manufacturer and a third-party company.
The company has also settled patent-infringement lawsuits for generic versions of AstraZeneca’s cholesterol drug Crestor (rosuvastatin calcium); Mallinckrodt’s painkiller Exalgo (hydromorphone); Mediciss acne drug Ziana (clindamycin phosphate; tretinoin); Medicis’ warts, actinic keratosis and basal cell carcinoma drug Zyclara (imiquimod); Shire’s hypertension and attention deficit hyperactivity disorder drug Intuniv (guanfacine); and an abuse-deterrent version of Purdue Pharma’s painkiller OxyContin (oxycodone).
Part of the company’s sales growth came from its branded drugs, such as the contraceptive Generess Fe (norethindrone and ethinyl estradiol tablets, ferrous fumarate chewable tablets), the enlarged prostate drug Rapaflo (silodosin), the menopause drug Crinone (progesterone) and the testosterone drug Androderm (testosterone).